Saulo Mendoza1, Olgica Trenchevska2, Sarah M King3, Randall W Nelson2, Dobrin Nedelkov2, Ronald M Krauss3, Hussein N Yassine4. 1. Department of Medicine, University of Southern California, Los Angeles, CA, USA. 2. Molecular Biomarkers Laboratory, The Biodesign Institute, Arizona State University, Tempe, AZ, USA. 3. Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, CA, USA. 4. Department of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: hyassine@usc.edu.
Abstract
BACKGROUND: The presence of small dense low-density lipoprotein (LDL) is associated with obesity, type II diabetes, and an increased risk for cardiovascular disease. Apolipoprotein C-III (apoC-III) is involved in the formation of small dense LDL, but the exact mechanisms are still not well defined. ApoC-III is a glycosylated apolipoprotein, with 3 major glycoforms: apoC-III0, apoC-III1, and apoC-III2 that contain 0, 1, or 2 molecules of sialic acid, respectively. In our previous work, we reported an association among apoC-III0 and apoC-III1, but not apoC-III2 with fasting plasma triglyceride levels in obesity and type II diabetes. OBJECTIVE: The goal of this study was to determine the relationship between changes in the major apoC-III glycoforms and small dense LDL levels after dietary interventions. METHODS: Mass spectrometric immunoassay was performed on fasting plasma samples from 61 subjects who underwent either a high-carbohydrate diet (n = 34) or a weight loss intervention (n = 27). RESULTS: After both dietary interventions, changes in total apoC-III concentrations were associated with changes in LDL peak particle diameter (r = -0.58, P < .0001). Increases in total apoC-III concentrations after the high-carbohydrate diet were associated with decreases in LDL size (r = -0.53, P = .001), and decreases in apoC-III concentrations after weight loss were associated with increases in LDL peak particle diameter (r = -0.54, P = .004). Changes in concentrations of apoC-III1 and apoC-III0, but not apoC-III2, were associated with changes in LDL peak particle diameter in both the weight loss and high-carbohydrate interventions. CONCLUSIONS: We conclude that apoC-III0 and apoC-III1, but not apoC-III2 are associated with the formation of small dense LDL.
BACKGROUND: The presence of small dense low-density lipoprotein (LDL) is associated with obesity, type II diabetes, and an increased risk for cardiovascular disease. Apolipoprotein C-III (apoC-III) is involved in the formation of small dense LDL, but the exact mechanisms are still not well defined. ApoC-III is a glycosylated apolipoprotein, with 3 major glycoforms: apoC-III0, apoC-III1, and apoC-III2 that contain 0, 1, or 2 molecules of sialic acid, respectively. In our previous work, we reported an association among apoC-III0 and apoC-III1, but not apoC-III2 with fasting plasma triglyceride levels in obesity and type II diabetes. OBJECTIVE: The goal of this study was to determine the relationship between changes in the major apoC-III glycoforms and small dense LDL levels after dietary interventions. METHODS: Mass spectrometric immunoassay was performed on fasting plasma samples from 61 subjects who underwent either a high-carbohydrate diet (n = 34) or a weight loss intervention (n = 27). RESULTS: After both dietary interventions, changes in total apoC-III concentrations were associated with changes in LDL peak particle diameter (r = -0.58, P < .0001). Increases in total apoC-III concentrations after the high-carbohydrate diet were associated with decreases in LDL size (r = -0.53, P = .001), and decreases in apoC-III concentrations after weight loss were associated with increases in LDL peak particle diameter (r = -0.54, P = .004). Changes in concentrations of apoC-III1 and apoC-III0, but not apoC-III2, were associated with changes in LDL peak particle diameter in both the weight loss and high-carbohydrate interventions. CONCLUSIONS: We conclude that apoC-III0 and apoC-III1, but not apoC-III2 are associated with the formation of small dense LDL.
Authors: Stephen B Harvey; Yan Zhang; Joshua Wilson-Grady; Teresa Monkkonen; Gary L Nelsestuen; Raj S Kasthuri; Michael R Verneris; Troy C Lund; E Wesley Ely; Gordon R Bernard; Harald Zeisler; Monika Homoncik; Bernd Jilma; Therese Swan; Todd A Kellogg Journal: J Proteome Res Date: 2009-02 Impact factor: 4.466
Authors: Patty W Siri-Tarino; Paul T Williams; Harriet S Fernstrom; Robin S Rawlings; Ronald M Krauss Journal: Obesity (Silver Spring) Date: 2009-06-04 Impact factor: 5.002
Authors: Chunyu Zheng; Veronica Azcutia; Elena Aikawa; Jose-Luiz Figueiredo; Kevin Croce; Hiroyuki Sonoki; Frank M Sacks; Francis W Luscinskas; Masanori Aikawa Journal: Eur Heart J Date: 2012-08-26 Impact factor: 29.983
Authors: Nicholas G Norwitz; Adrian Soto-Mota; Bob Kaplan; David S Ludwig; Matthew Budoff; Anatol Kontush; David Feldman Journal: Metabolites Date: 2022-05-20
Authors: Natalie C Kegulian; Bastian Ramms; Steven Horton; Olgica Trenchevska; Dobrin Nedelkov; Mark J Graham; Richard G Lee; Jeffrey D Esko; Hussein N Yassine; Philip L S M Gordts Journal: Arterioscler Thromb Vasc Biol Date: 2019-08-08 Impact factor: 10.514
Authors: Yoriko Heianza; Tao Zhou; Hua He; Joseph A DiDonato; George A Bray; Frank M Sacks; Lu Qi Journal: Int J Obes (Lond) Date: 2021-08-23 Impact factor: 5.095